The investment in New Jersey is the first step of a multi-year site expansion program, aimed at advancing both spray drying and tableting capabilities, Hovione said. Simultaneously, the spray drying capacity at the Cork facility was increases nearly twofold.

Jean-Luc Herbeaux, CEO of Hovione said: “These expansions, incorporating our latest technologies, reflect Hovione’s unwavering commitment to innovation and manufacturing service excellence. Strengthening our facilities and teams in the USA and Ireland allows us to better serve our customers and provide flexible supply options for both small- and large-scale programs. By increasing our capacity and enhancing our technological capabilities, we are even better equipped to help our customers bring new and more complex drugs to market.”

According to Hovione, the investments at both sites are part of the company’s long-term strategy to remain at the forefront of pharmaceutical technology.